Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies

Gerardo Rosati(Ospedale San Carlo), Roberto Bordonaro(Ospedale Garibaldi), G Caputo, Giorgio Reggiardo(Data Management (Italy)), Giusi Blanco(Associazione Italiana Di Oncologia Medica), Alessandra Tucci(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), G. Novello(Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Alfredo Butera(Nuovo Ospedale San Giovanni di Dio), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Stefano Cordio(Ospedale San Carlo)
Annals of Oncology
July 1, 2019
10.1093/annonc/mdz155.072
Cited by 0

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452